BIS Monitor Anesthesia for Neurocognitive Disorder
(POEGEA Trial)
Trial Summary
What is the purpose of this trial?
The objective of the study is to investigate, in patients aged 70 years and over undergoing major non-cardiac surgery, the effect of electroencephalic (EEG)-guided anesthesia on postoperative neurocognitive disorders when controlling for intraoperative nociception, personalized blood pressure targets and using full information provided by the processed EEG monitor (including burst suppression ratio, density spectral array and raw EEG waveform). This prospective, randomized, controlled trial will be conducted in a single Canadian university hospital. Patients aged 70 years and over, undergoing elective major non-cardiac surgery will be included. The administration of sevoflurane will be adjusted to maintain a BIS value between 40 and 60, a suppression Ratio at 0%, a direct EEG display without any suppression time and a spectrogram with most of the EEG wave frequency within the alpha, theta and delta frequencies in the EEG-guided group. In the control group sevoflurane will be administered to achieve an age-adjusted minimum alveolar concentration of \[0.8-1.2\]. A nociception monitor will guide intraoperative opioids' infusion and individual blood pressure targets will be personalized in both groups. The primary endpoint is the incidence of neurocognitive disorder (NCD) at postoperative day 1 evaluated by the Montréal Cognitive Assessment. Secondary endpoints include the incidence of postoperative neurocognitive disorder at different timepoints and the evaluation of cognitive trajectories among EEG-guided and control groups.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of EEG-guided anesthesia for neurocognitive disorder?
Is BIS Monitor Anesthesia safe for humans?
How is EEG-guided anesthesia different from other treatments for neurocognitive disorder?
EEG-guided anesthesia, using the Bispectral Index (BIS), is unique because it monitors brain activity to ensure the right depth of anesthesia, reducing the risk of awareness during surgery. This approach is different from standard methods that rely solely on anesthetic gas levels, offering a more precise way to manage anesthesia.1491011
Research Team
Philippe Richebé, MD, PhD
Principal Investigator
Hôpital Maisonneuve-Rosemont - CIUSSS de l'Est de l'Ile de Montréal - Canada
Eligibility Criteria
This trial is for patients aged 70 or older who are undergoing major non-cardiac surgery and have an expected anesthesia time over 60 minutes. They must be able to communicate in English or French, without severe cognitive impairments from conditions like dementia, and not require emergency surgery.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo EEG-guided or standard care anesthesia during major non-cardiac surgery
Postoperative Monitoring
Participants are assessed for neurocognitive disorders and other outcomes at multiple postoperative timepoints
Follow-up
Participants are monitored for long-term cognitive outcomes and quality of life
Treatment Details
Interventions
- Electroencephalic (EEG)-guided anesthesia
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ciusss de L'Est de l'Île de Montréal
Lead Sponsor
Medtronic
Industry Sponsor
Geoff Martha
Medtronic
Chief Executive Officer since 2020
Finance degree from Penn State University
Dr. Richard Kuntz
Medtronic
Chief Medical Officer since 2023
MD, MSc